Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

This trial is testing a combination regimen of azacytidine plus the CAOLD chemotherapy drugs for people with angioimmunoblastic T-cell lymphoma (AITL) — a specific type of T-cell lymphoma — that has come back or stopped responding to at least one prior treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of angioimmunoblastic T-cell lymphoma (AITL) - Your lymphoma has relapsed after, or never responded to, at least one prior round of systemic therapy - Your blood counts meet the minimum required levels (white cells, platelets) - You are willing to commit to the study visit schedule **You may NOT be eligible if...** - You have active, uncontrolled infections - You have significant liver, kidney, or heart problems that make chemotherapy unsafe - You have another active malignancy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.